Assessing Hepatitis B Reactivation Risk With Rituximab and Recent Intravenous Immunoglobulin Therapy
Claire Dysart1, Karine Rozenberg-Ben-Dror2, Mariscelle Sales3
1Department of Veterans Affairs, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin, USA.
Open Forum Infectious Diseases
|March 27, 2020
Abstract:
Hepatitis B reactivation (HBR) is a complication of immunosuppression associated with significant morbidity and mortality. To further complicate interpretation of hepatitis B serologies, false positivity can occur in patients with recent intravenous immunoglobulin exposure. This scenario is not well recognized and may lead to inappropriate prescribing of HBR prophylaxis.


